Outcomes after liver transplantation: Keep the end in mind

Journal of Pediatric Gastroenterology and Nutrition

Volumn 43, Issue 1 SUPPL. 1, 2006, Pages

  Bucuvalas, John C ^a,b   Campbell, Kathleen M ^a,b   Cole, Conrad R ^c   Guthery, Stephen L ^d  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Children; Clinical outcomes; Cost; Health related quality of life; Improvement

Indexed keywords

CHILD; GRAFT SURVIVAL; HEALTH CARE DELIVERY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LIVER DISEASE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SURVIVAL; SURVIVAL RATE;

ADOLESCENT; BILIARY ATRESIA; BONE DENSITY; BONE DISEASES; CALCINEURIN; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; CYCLOSPORINE; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFORMATION SERVICES; KIDNEY FAILURE, CHRONIC; LENGTH OF STAY; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; MALE; OHIO; POSTOPERATIVE COMPLICATIONS; QUALITY OF LIFE; RISK FACTORS; TACROLIMUS; TREATMENT OUTCOME;

EID: 33745754679     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpg.0000226389.64236.dc     Document Type: Review

References (54)

1. Merion RM, Schaubel DE, Dykstra DM, et al. The survival benefit of liver transplantation. Am J Transplant 2005;5:307-13.
2. Freeman RB, Wiesner RH, Edwards E, et al. Results of the first year of the new liver allocation plan. Liver Transpl 2004;10:7-15.
3. Freeman RB. Overview of the MELD/PELD system of liver allocation indications for liver transplantation in the MELD era: evidence-based patient selection. Liver Transpl 2004;10:S2-S3.
4. Freeman RB. MELD and the quality of life. Liver Transpl 2005;11:134-6.
5. Physicians Desk Reference. Montvale, NJ: Thompson, 2006.
6. Magee J, Bucuvalas J, Farmer D, et al. SRTR Report on the State of Transplantation: Pediatric Transplantation. Am J Transplan 2004;4:54-71.
7. Roberts JP, Hulbert-Shearon TE, Merion RM, et al. Influence of graft type on outcomes after pediatric liver transplantation. Am J Transplant 2004;4:373-7.
8. Wagner EH, Glasgow RE, Davis C, et al. Quality improvement in chronic illness care: a collaborative approach. Jt Comm J Qual Improv 2001;27:63-80.
9. Crossing the Quality Chasm. Washington DC: National Academy Press; 2001.
10. Godfrey MM, Nelson EC, Wasson JH, et al. Microsystems in health care: Part 3. Planning patient-centered services. Jt Comm J Qual Saf 2003;29:159-70.
11. Nelson EC, Batalden PB, Homa K, et al. Microsystems in health care: Part 2. Creating a rich information environment. Jt Comm J Qual Saf 2003;29:5-15.
12. Nelson EC, Batalden PB, Huber TP, et al. Microsystems in health care: Part 1. Learning from high-performing front-line clinical units. Jt Comm J Qual Improv 2002;28:472-93.
13. Batalden PB, Mohr JJ, Nelson EC, et al. Improving health care, Part 4: Concepts for improving any clinical process. Jt Comm J Qual Improv 1996;22:651-9.
14. Mohr JJ, Mahoney CC, Nelson EC, et al. Improving health care, Part 3: Clinical benchmarking for best patient care. Jt Comm J Qual Improv 1996;22:599-616.
15. Nelson EC. Using outcomes measurement to improve quality and value. New Dir Ment Health Serv 1996:111-24.
16. Arnold JC, Hauser D, Ziegler R, et al. Bone disease after liver transplantation. Transplant Proc 1992;24:2709-10.
17. Eastell R, Dickson ER, Hodgson SF, et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 1991;14:296-300.
18. Floreani A, Fries W, Luisetto G, et al. Bone metabolism in orthotopic liver transplantation: a prospective study. Liver Transpl Surg 1998;4:311-9.
19. Haagsma EB, Thijn CJ, Post JG, et al. Bone disease after orthotopic liver transplantation. J Hepatol 1988;6:94-100.
20. Hussaini SH, Oldroyd B, Stewart SP, et al. Effects of orthotopic liver transplantation on body composition. Liver 1998;18:173-9.
21. Meys E, Fontanges E, Fourcade N. Bone loss after orthotopic liver transplantation. Am J Med 1994;97:445-50.
22. Porayko MK, Wiesner RH, Hay JE, et al. Bone disease in liver transplant recipients: incidence, timing, and risk factors. Transplant Proc 1991;23(1 Pt 2):1462-5.
23. Pou L, Brunet M, Bilbao I, et al. Therapeutic drug monitoring of tacrolimus in liver transplantation, phase III FK506 multicenter Spanish Study Group: a two-year follow-up. Ther Drug Monit 1998;20:602-6.
24. Guthery SL, Pohl JF, Bucuvalas JC, et al. Bone mineral density in long-term survivors following pediatric liver transplantation. Liver Transpl 2003;9:365-70.
25. Wheatley HC, Datzman M, Williams JW, et al. Long-term effects of cyclosporine on renal function in liver transplant recipients. Transplantation 1987;43:641-7.
26. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003;9:741-7.
27. Distant DA, Gonwa TA. The kidney in liver transplantation. J Am Soc Nephrol 1993;4:129-36.
28. Gonwa TA, Morris CA, Goldstein RM, et al. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome - experience in 300 patients. Transplantation 1991;51:428-30.
29. Fung JJ, Alessiani M, Abu-Elmagd K, et al. Adverse effects associated with the use of FK 506. Transplant Proc 1991;23:3105-8.
30. Cohen AJ, Stegall MD, Rosen CB, et al. Chronic renal dysfunction late after liver transplantation. Liver Transpl 2002;8:916-21.
31. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-40.
32. Fisher NC, Nightingale PG, Gunson BK, et al. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998;66:59-66.
33. Skinner R, Cole M, Pearson AD, et al. Inaccuracy of glomerular filtration rate estimation from height/plasma creatinine ratio. Arch Dis Child 1994;70:387-90.
34. Seikaly MG, Browne R, Bajaj G, et al. Limitations to body length/serum creatinine ratio as an estimate of glomerular filtration in children. Pediatr Nephrol 1996;10:709-11.
35. Campbell KM, Yazigi N, Ryckman FC, et al. High prevalence of renal dysfunction in long-term survivors after pediatric liver transplantation. J Pediatr 2006;148:475-80.
36. Bucuvalas JC, Britto M, Krug S, et al. Health-related quality of life in pediatric liver transplant recipients: A single-center study. Liver Transpl 2003;9:62-71.
37. Cole CR, Bucuvalas JC, Hornung RW, et al. Impact of liver transplantation on HRQOL in children less than 5 years old. Pediatr Transplant 2004;8:222-7.
38. Varni JW, Seid M, Smith Knight T, et al. The PedsQL in pediatric rheumatology: reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory Generic Core Scales and Rheumatology Module. Arthritis Rheum 2002;46:714-25.
39. Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care 2001;39:800-12.
40. Bucuvalas JC, Ryckman FC, Atherton H, et al. Predictors of cost of liver transplantation in children: A single center study. J Pediatr 2001;139:66-74.
41. Cole CR, Bucuvalas JC, Hornung R, et al. Outcome after pediatric liver transplantation impact of living donor transplantation on cost. J Pediatr 2004;144:729-35.
42. Armstrong VW, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem 2001;34:9-16.
43. Hedayat S, Kershner RP, Su G. Relationship of whole-blood FK506 concentrations to rejection and toxicity in liver and kidney transplants. J Biopharm Stat 1996;6:411-24.
44. Henry ML. Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. Clin Transplant 1999;13:209-20.
45. Hochleitner BW, Bosmuller C, Nehoda H, et al. Increased tacrolimus levels during diarrhea. Transpl Int 2001;14:230-3.
46. Kahan BD, Keown P, Levy GA, et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002;24:330-350. Discussion 329.
47. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996;62: 920-6.
48. Lo A, Burckart GJ. P-glycoprotein and drug therapy in organ transplantation. J Clin Pharmacol 1999;39:995-1005.
49. Lieberman R, McMichael J. Role of pharmacokinetic-pharmacodynamic principles in rational and cost-effective drug development. Ther Drug Monit 1996;18:423-8.
50. Manzanares C. Therapeutic drug monitoring of tacrolimus: a moving matter. Therapie 2002;57:133-6.
51. Staatz CE, Taylor PJ, Lynch SV, et al. A pharmacodynamic investigation of tacrolimus in pediatric liver transplantation. Liver Transpl 2004;10:506-12.
52. Wong SH. Therapeutic drug monitoring for immunosuppressants. Clin Chim Acta 2001;313:241-53.
53. Wheeler DJ. Understanding Variation: The Key to managing Chaos, 2nd ed. Knoxville, TN: SPC Press, 2000.
54. Landgraf J, Abetz L, Ware J. The Child Health Questionnaire (CHQ): A User's Manual, 1st ed. Boston MA: The Health Institute, New England Medical Center, 1996.